[go: up one dir, main page]

PE20081505A1 - Inhibidores de serina palmitoiltransferasa - Google Patents

Inhibidores de serina palmitoiltransferasa

Info

Publication number
PE20081505A1
PE20081505A1 PE2007001803A PE2007001803A PE20081505A1 PE 20081505 A1 PE20081505 A1 PE 20081505A1 PE 2007001803 A PE2007001803 A PE 2007001803A PE 2007001803 A PE2007001803 A PE 2007001803A PE 20081505 A1 PE20081505 A1 PE 20081505A1
Authority
PE
Peru
Prior art keywords
alkyl
oxo
halogen
chlorophenyl
dihydro
Prior art date
Application number
PE2007001803A
Other languages
English (en)
Inventor
Gary Louis Bolton
Richard Henry Hutchings
William Keun Chan Park
Huis Chad Alan Van
Jeffrey Thomas Kohrt
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20081505A1 publication Critical patent/PE20081505A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE INDOLINONA, BENCIMIDAZOLONA O BENZOXAZOLONA DE FORMULA (I), DONDE E1 ES N O CH; E2 ES NR, O O CRaRb; R ES H, ALQUILO C1-C3, CH2-COOH, CH2-COO-ALQUILO C1-C6; Ra Y Rb SON H O ALQUILO C1-C3; LA LINEA PUNTEADA INDICA UN DOBLE ENLACE OPCIONAL; r ES UN ENTERO DE 0 A 2; r' Y r'' SON UN ENTERO DE 1 A 3; X ES H, HALOGENO, HALOGENO, OXO; =NOR'; R' ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; m Y n SON UN ENTERO DE 0 A 2; A ES ALQUILO C1-C6, ALQUENILO C2-C6, UN CARBOCICLO, ENTRE OTROS; R1 ES H, HALOGENO, CN, C(O)R5, ENTRE OTROS; R2 ES H, HALOGENO, CF3, ALCOXI C1-C3, ALQUILO C1-C3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: METILAMIDA DEL ACIDO 1-{1-[2-(4-CLOROFENIL)-2-OXOETILPIPERIDIN-4-IL}-2-OXO-2,3-DIHIDRO-1H-BENZOIMIDAZOL-5-CARBOXILICO, METILAMIDA DEL ACIDO 1-{1-[2-(4-CLOROFENIL)-2-OXOETIL]PIPERIDIN-4-IL}-6-FLUORO-2-OXO-2,3-DIHIDRO-1H-BENZOIMIDAZOL-5-CARBOXILICO, ESTER METILICO DEL ACIDO 1-{1-[2-(4-CLOROFENIL)-2-OXOETIL]PIPERIDIN-4-IL}-6-FLUORO-2-OXO-2,3-DIHIDRO-1H-BENZOIMIDAZOL-5-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA SERINA PALMITOILTRANSFERASA Y SON UTILES EN EL TRATAMIENTO DE LA DIABETES TIPO 2, RESISTENCIA A LA INSULINA, SINDROME METABOLICO, ENTRE OTROS
PE2007001803A 2006-12-20 2007-12-14 Inhibidores de serina palmitoiltransferasa PE20081505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87598806P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081505A1 true PE20081505A1 (es) 2008-10-24

Family

ID=39361479

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001803A PE20081505A1 (es) 2006-12-20 2007-12-14 Inhibidores de serina palmitoiltransferasa

Country Status (10)

Country Link
US (1) US20080287479A1 (es)
EP (1) EP2121656A1 (es)
JP (1) JP2010513456A (es)
AR (1) AR064423A1 (es)
CA (1) CA2671138A1 (es)
CL (1) CL2007003733A1 (es)
PE (1) PE20081505A1 (es)
TW (1) TW200831487A (es)
UY (1) UY30807A1 (es)
WO (1) WO2008084300A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090284A1 (it) * 2009-02-26 2010-08-27 Consiglio Nazionale Ricerche Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers
FR2967673B1 (fr) 2010-11-24 2012-12-28 Minakem Synthese de n-heterocycles par alkylation reductrice de derives cyanes
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
AP3649A (en) 2011-02-23 2016-03-18 Lupin Ltd Heteroaryl derivatives as alpha7 nachr modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2866015A1 (en) 2012-03-06 2013-09-12 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9273067B2 (en) * 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
JP6706250B2 (ja) * 2015-04-20 2020-06-03 武田薬品工業株式会社 複素環化合物
CA3041266A1 (en) * 2016-10-18 2018-04-26 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7374772B2 (ja) * 2017-07-05 2023-11-07 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する有害生物防除的に活性な複素環式誘導体
CN108689875A (zh) * 2018-07-18 2018-10-23 陕西恒润化学工业有限公司 一种环酰菌胺及其合成方法
EA202191113A1 (ru) 2018-10-30 2021-09-17 Дау Глоубл Текнолоджиз Ллк Получение гидроксиэтилпиперазина
US12187723B2 (en) 2019-05-09 2025-01-07 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
JP7482324B2 (ja) * 2020-10-08 2024-05-13 メルク・シャープ・アンド・ドーム・エルエルシー 新規なジアシルグリセリドo-アシルトランスフェラーゼ2阻害剤としてのオキシインドール誘導体の製造
MX2023003842A (es) 2020-10-08 2023-04-14 Merck Sharp & Dohme Llc Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325499A (en) * 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
WO1996030381A1 (en) * 1995-03-28 1996-10-03 Novo Nordisk A/S Immunosuppressive agents
EP0898568B1 (en) * 1996-04-19 2006-10-04 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP1379246B1 (en) * 2001-04-18 2008-10-08 Euro-Celtique S.A. Nociceptin analogs
CA2444595A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
JP2008515987A (ja) * 2004-10-12 2008-05-15 フォーブス メディ−テック(リサーチ) インコーポレーテッド インシュリン抵抗性及び心筋ミオパチーを治療する化合物及び方法

Also Published As

Publication number Publication date
JP2010513456A (ja) 2010-04-30
CA2671138A1 (en) 2008-07-17
CL2007003733A1 (es) 2008-07-18
TW200831487A (en) 2008-08-01
EP2121656A1 (en) 2009-11-25
UY30807A1 (es) 2008-07-31
WO2008084300A1 (en) 2008-07-17
US20080287479A1 (en) 2008-11-20
AR064423A1 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
PE20081505A1 (es) Inhibidores de serina palmitoiltransferasa
PE20090159A1 (es) COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20091841A1 (es) Inhibidores del virus de hepatitis c
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20081532A1 (es) Compuestos novedosos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20080519A1 (es) Derivados de ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)pirimidin-4-iloxi]-piperidina-1-carboxilico y sus composiciones farmaceuticas
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20081659A1 (es) Agonistas de gpcr
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20120812A1 (es) Compuestos vinil indazolilo
UY28493A1 (es) Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento.
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace

Legal Events

Date Code Title Description
FA Abandonment or withdrawal